Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

BMB. 2023; 8(3): 317-324


Turkish clinician's opinion about COVID treatment in 2nd and 3rd level hospitals What did change from 2021 to 2022 ? Results of 2 years of follow up. 2 ve 3.Basamak Hastanelerin COVID servislerinde çalışan klinisyenlerin tedavi seçeneklerine bakışı. 2021 den 2022 ye ne değişti? 2 yıllık sonuçların değerlendirilmesi. Turkish clinicians opinion changings in 2 years about the COVID treatment

MEHMET BURAK AKTUĞLU.




Abstract

Objective : To determine the change in opinion about the treatment options of Turkish doctors who fight COVID in 2nd and 3rd level hospitals.
Method: A questionnary compromised of 14 questions is asked to clinicians in may 20221 and may 2022. The results are collected with Data alchemer, and the results are analyzed with IBM SPSS.
Results: Prednisolone, IV use of 60 and 80 mg when added to standart therapies was observed by clinicians more effective in 2022 than in 2021. Also, use of high doses of prednisolone (250 mg and higher) was defined trustworty in both years. ASA is used in routine treatment in both years. But there was a small decrease of trust in its effectiveness in 2022 than in 2021. Low Molecular Weight Heparine(LMWH), (especially Enoxaparine) is also used in the treatment of COVID for both years and a quite higher level of trust in its effectiveness was observed in 2022 than in 2021. For vaccines, use of BİONTECH is preferred by doctors, for themselves and their relatives if it is present.
Conclusion: During the pandemic, clinicians all over the world used a lot of treatment options to gain control over COVID, at the end it is well understood that there was no specific treatment but vaccines, steroids, ASA, low molecular weight heparin were the best agents to be used against symptoms and complications of COVID.In Turkiye also,as we concluded after our study ,clinicians are in favour of same medical agents as their global colleagues.
Keywords: COVID, Treatment,options, clinician, opinion

Key words: COVID, Treatment, options Clinician, Opinion,






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.